Influence of Sex in the Development of Liver Diseases

Abstract

The liver is a sexually dimorphic organ. Sex differences in prevalence, progression, prognosis, and treatment prevail in most liver diseases, and the mechanism of how liver diseases act differently among male versus female patients has not been fully elucidated. Biological sex differences in normal physiology and disease arise principally from sex hormones and/or sex chromosomes. Sex hormones contribute to the development and progression of most liver diseases, with estrogen- and androgen-mediated signaling pathways mechanistically involved. In addition, genetic factors in sex chromosomes have recently been found to contribute to the sex disparity of many liver diseases, which might explain, to some extent, the difference in gene expression pattern, immune response, and xenobiotic metabolism between men and women. Although increasing evidence suggests that sex is one of the most important modulators of disease prevalence and outcomes, at present, basic and clinical studies have long been sex unbalanced, with female subjects underestimated. As such, this review focuses on sex disparities of liver diseases and summarizes the current understanding of sex-specific mechanisms, including sex hormones, sex chromosomes, etc. We anticipate that understanding sex-specific pathogenesis will aid in promoting personalized therapies for liver disease among male versus female patients.

Keywords

sex - liver disease - sex hormones - sex chromosome

Authors' Contributions

X-F.Z. and Y.L. conceived and mentored this study. J-W.Z. and N.Z. acquired and analyzed data, and wrote the draft of the manuscript. X-F.Z. and Y.L. wrote and revised the manuscript.

Publication History

Accepted Manuscript online:
14 January 2025

Article published online:
11 February 2025

• References

• 1 Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol 2023; 79 (02) 516-537
• 2 Heron M. Deaths: leading causes for 2017. Natl Vital Stat Rep 2019; 68 (06) 1-77
• 3 Woitowich NC, Woodruff TK. Opinion: Research community needs to better appreciate the value of sex-based research. Proc Natl Acad Sci U S A 2019; 116 (15) 7154-7156
• 4 Mauvais-Jarvis F, Bairey Merz N, Barnes PJ. et al. Sex and gender: modifiers of health, disease, and medicine. Lancet 2020; 396 (10250): 565-582
• 5 Roy AK, Chatterjee B. Sexual dimorphism in the liver. Annu Rev Physiol 1983; 45: 37-50
• 6 Yang X, Schadt EE, Wang S. et al. Tissue-specific expression and regulation of sexually dimorphic genes in mice. Genome Res 2006; 16 (08) 995-1004
• 7 Man S, Deng Y, Ma Y. et al. Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: a nationwide study with 5.7 million adults in China. Gastroenterology 2023; 165 (04) 1025-1040
• 8 Lefebvre P, Staels B. Hepatic sexual dimorphism - implications for non-alcoholic fatty liver disease. Nat Rev Endocrinol 2021; 17 (11) 662-670
• 9 Caballería L, Pera G, Arteaga I. et al. High prevalence of liver fibrosis among european adults with unknown liver disease: a population-based study. Clin Gastroenterol Hepatol 2018; 16 (07) 1138-1145.e5
• 10 Lonardo A, Nascimbeni F, Ballestri S. et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology 2019; 70 (04) 1457-1469
• 11 Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349 (9055): 825-832
• 12 Floreani A, Bizzaro D, Shalaby S, Taliani G, Burra P. Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF). Sex disparity and drug-induced liver injury. Dig Liver Dis 2023; 55 (01) 21-28
• 13 Szabo G. Women and alcoholic liver disease - warning of a silent danger. Nat Rev Gastroenterol Hepatol 2018; 15 (05) 253-254
• 14 Kezer CA, Simonetto DA, Shah VH. Sex differences in alcohol consumption and alcohol-associated liver disease. Mayo Clin Proc 2021; 96 (04) 1006-1016
• 15 Invernizzi F, Cilla M, Trapani S. et al; Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF). Gender and autoimmune liver diseases: relevant aspects in clinical practice. J Pers Med 2022; 12 (06) 12
• 16 Barone M, Margiotta M, Scavo MP. et al. Possible involvement of androgen receptor alterations in hepatocarcinogenesis. Dig Liver Dis 2009; 41 (09) 665-670
• 17 Besse-Patin A, Léveillé M, Oropeza D, Nguyen BN, Prat A, Estall JL. Estrogen signals through peroxisome proliferator-activated receptor-γ coactivator 1α to reduce oxidative damage associated with diet-induced fatty liver disease. Gastroenterology 2017; 152 (01) 243-256
• 18 Li W, Li D, Sun L, Li Z, Yu L, Wu S. The protective effects of estrogen on hepatic ischemia-reperfusion injury in rats by downregulating the Ang II/AT1R pathway. Biochem Biophys Res Commun 2018; 503 (04) 2543-2548
• 19 Wang SH, Yeh SH, Lin WH. et al. Estrogen receptor α represses transcription of HBV genes via interaction with hepatocyte nuclear factor 4α. Gastroenterology 2012; 142 (04) 989-998.e4
• 20 Klair JS, Yang JD, Abdelmalek MF. et al; Nonalcoholic Steatohepatitis Clinical Research Network. A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. Hepatology 2016; 64 (01) 85-91
• 21 Nuermaimaiti A, Chang L, Yan Y. et al. The role of sex hormones and receptors in HBV infection and development of HBV-related HCC. J Med Virol 2023; 95 (12) e29298
• 22 Liu C, Ren YF, Dong J. et al. Activation of SRY accounts for male-specific hepatocarcinogenesis: Implication in gender disparity of hepatocellular carcinoma. Cancer Lett 2017; 410: 20-31
• 23 Murakami S, Chishima S, Uemoto H. et al. The male-specific factor Sry harbors an oncogenic function. Oncogene 2014; 33 (23) 2978-2986
• 24 Murakami S, Ninomiya W, Sakamoto E, Shibata T, Akiyama H, Tashiro F. SRY and OCT4 are required for the acquisition of cancer stem cell-like properties and are potential differentiation therapy targets. Stem Cells 2015; 33 (09) 2652-2663
• 25 Tsuei DJ, Lee PH, Peng HY. et al. Male germ cell-specific RNA binding protein RBMY: a new oncogene explaining male predominance in liver cancer. PLoS One 2011; 6 (11) e26948
• 26 Yin YH, Li YY, Qiao H. et al. TSPY is a cancer testis antigen expressed in human hepatocellular carcinoma. Br J Cancer 2005; 93 (04) 458-463
• 27 Dong J, Ke MY, Wu XN. et al. SRY is a key mediator of sexual dimorphism in hepatic ischemia/reperfusion injury. Ann Surg 2022; 276 (02) 345-356
• 28 Wu XN, Wang MZ, Zhang N. et al. Sex-determining region Y gene promotes liver fibrosis and accounts for sexual dimorphism in its pathophysiology. J Hepatol 2024; 80 (06) 928-940
• 29 Donnelly MC, Davidson JS, Martin K, Baird A, Hayes PC, Simpson KJ. Acute liver failure in Scotland: changes in aetiology and outcomes over time (the Scottish Look-Back Study). Aliment Pharmacol Ther 2017; 45 (06) 833-843
• 30 Weaver RJ, Blomme EA, Chadwick AE. et al. Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models. Nat Rev Drug Discov 2020; 19 (02) 131-148
• 31 Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005; 4 (06) 489-499
• 32 Chalasani N, Bonkovsky HL, Fontana R. et al; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148 (07) 1340-52.e7
• 33 Amacher DE. Female gender as a susceptibility factor for drug-induced liver injury. Hum Exp Toxicol 2014; 33 (09) 928-939
• 34 Shen T, Liu Y, Shang J. et al. Incidence and etiology of drug-induced liver injury in Mainland China. Gastroenterology 2019; 156 (08) 2230-2241.e11
• 35 Sgro C, Clinard F, Ouazir K. et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36 (02) 451-455
• 36 Lucena MI, Andrade RJ, Kaplowitz N. et al; Spanish Group for the Study of Drug-Induced Liver Disease. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009; 49 (06) 2001-2009
• 37 Andrade RJ, Lucena MI, Fernández MC. et al; Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129 (02) 512-521
• 38 Reuben A, Koch DG, Lee WM. Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52 (06) 2065-2076
• 39 Dai G, He L, Chou N, Wan YJ. Acetaminophen metabolism does not contribute to gender difference in its hepatotoxicity in mouse. Toxicol Sci 2006; 92 (01) 33-41
• 40 Du K, Williams CD, McGill MR, Jaeschke H. Lower susceptibility of female mice to acetaminophen hepatotoxicity: role of mitochondrial glutathione, oxidant stress and c-jun N-terminal kinase. Toxicol Appl Pharmacol 2014; 281 (01) 58-66
• 41 Rohrer PR, Rudraiah S, Goedken MJ, Manautou JE. Is nuclear factor erythroid 2-related factor 2 responsible for sex differences in susceptibility to acetaminophen-induced hepatotoxicity in mice?. Drug Metab Dispos 2014; 42 (10) 1663-1674
• 42 Rubin JB, Hameed B, Gottfried M, Lee WM, Sarkar M. Acute Liver Failure Study Group. Acetaminophen-induced acute liver failure is more common and more severe in women. Clin Gastroenterol Hepatol 2018; 16 (06) 936-946
• 43 Kjartansdottir I, Bergmann OM, Arnadottir RS, Björnsson ES. Paracetamol intoxications: a retrospective population-based study in Iceland. Scand J Gastroenterol 2012; 47 (11) 1344-1352
• 44 Sami F, Berg S, Manadan AM, Mycyk MB. Acetaminophen overdose: analysis of 2018 US nationwide emergency database. Intern Emerg Med 2024; 19 (06) 1727-1732
• 45 Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH. ACG Clinical Guideline: alcoholic liver disease. Am J Gastroenterol 2018; 113 (02) 175-194
• 46 Müller C. Liver, alcohol and gender. Wien Med Wochenschr 2006; 156 (19–20): 523-526
• 47 Sayaf K, Gabbia D, Russo FP, De Martin S. The role of sex in acute and chronic liver damage. Int J Mol Sci 2022; 23 (18) 23
• 48 Erol A, Karpyak VM. Sex and gender-related differences in alcohol use and its consequences: contemporary knowledge and future research considerations. Drug Alcohol Depend 2015; 156: 1-13
• 49 Gramenzi A, Caputo F, Biselli M. et al. Review article: alcoholic liver disease. –pathophysiological aspects and risk factors. Aliment Pharmacol Ther 2006; 24 (08) 1151-1161
• 50 Makri E, Goulas A, Polyzos SA. Epidemiology, pathogenesis, diagnosis and emerging treatment of nonalcoholic fatty liver disease. Arch Med Res 2021; 52 (01) 25-37
• 51 Nagral A, Bangar M, Menezes S. et al. Gender differences in nonalcoholic fatty liver disease. Euroasian J Hepatogastroenterol 2022; 12 (Suppl. 01) S19-S25
• 52 Balakrishnan M, Patel P, Dunn-Valadez S. et al. Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2021; 19 (01) 61-71.e15
• 53 Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122 (06) 1649-1657
• 54 Yang JD, Abdelmalek MF, Pang H. et al. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology 2014; 59 (04) 1406-1414
• 55 Hamaguchi M, Kojima T, Ohbora A, Takeda N, Fukui M, Kato T. Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women. World J Gastroenterol 2012; 18 (03) 237-243
• 56 Ter Horst KW, Gilijamse PW, de Weijer BA. et al. Sexual dimorphism in hepatic, adipose tissue, and peripheral tissue insulin sensitivity in obese humans. Front Endocrinol (Lausanne) 2015; 6: 182
• 57 Buday B, Pach PF, Literati-Nagy B. et al. Sex influenced association of directly measured insulin sensitivity and serum transaminase levels: why alanine aminotransferase only predicts cardiovascular risk in men?. Cardiovasc Diabetol 2015; 14: 55
• 58 Conrad N, Misra S, Verbakel JY. et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet 2023; 401 (10391): 1878-1890
• 59 Parikh-Patel A, Gold EB, Worman H, Krivy KE, Gershwin ME. Risk factors for primary biliary cirrhosis in a cohort of patients from the United States. Hepatology 2001; 33 (01) 16-21
• 60 Manns MP, Czaja AJ, Gorham JD. et al; American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51 (06) 2193-2213
• 61 Bambha K, Kim WR, Talwalkar J. et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003; 125 (05) 1364-1369
• 62 Singh S, Talwalkar JA. Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol 2013; 11 (08) 898-907
• 63 Weismüller TJ, Trivedi PJ, Bergquist A. et al; International PSC Study Group. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology 2017; 152 (08) 1975-1984.e8
• 64 Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115 (02) 209-218
• 65 Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol 2017; 14 (07) 397-411
• 66 Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2 (09) 533-543
• 67 El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132 (07) 2557-2576
• 68 Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 2013; 47 Suppl (00) S2-S6
• 69 Zhang XF, Liu Y, Li JH. et al. [Effect of splenectomy on the risk of hepatocellular carcinoma development among patients with liver cirrhosis and portal hypertension: a multi-institutional cohort study]. Zhonghua Wai Ke Za Zhi 2021; 59 (10) 821-828
• 70 Akinyemiju T, Abera S, Ahmed M. et al; Global Burden of Disease Liver Cancer Collaboration. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol 2017; 3 (12) 1683-1691
• 71 Zhai Y, Petrowsky H, Hong JC, Busuttil RW, Kupiec-Weglinski JW. Ischaemia-reperfusion injury in liver transplantation. –from bench to bedside. Nat Rev Gastroenterol Hepatol 2013; 10 (02) 79-89
• 72 Chen C, Hu LX, Dong T. et al. Apoptosis and autophagy contribute to gender difference in cardiac ischemia-reperfusion induced injury in rats. Life Sci 2013; 93 (07) 265-270
• 73 Crockett ET, Spielman W, Dowlatshahi S, He J. Sex differences in inflammatory cytokine production in hepatic ischemia-reperfusion. J Inflamm (Lond) 2006; 3: 16
• 74 Hundscheid IHR, Schellekens DHSM, Grootjans J. et al. Females are more resistant to ischemia-reperfusion-induced intestinal injury than males: a human study. Ann Surg 2020; 272 (06) 1070-1079
• 75 Rodríguez F, Nieto-Cerón S, Fenoy FJ. et al. Sex differences in nitrosative stress during renal ischemia. Am J Physiol Regul Integr Comp Physiol 2010; 299 (05) R1387-R1395
• 76 Zuo W, Zhang W, Chen NH. Sexual dimorphism in cerebral ischemia injury. Eur J Pharmacol 2013; 711 (1-3): 73-79
• 77 Michalopoulos GK, Bhushan B. Liver regeneration: biological and pathological mechanisms and implications. Nat Rev Gastroenterol Hepatol 2021; 18 (01) 40-55
• 78 Bizzaro D, Crescenzi M, Di Liddo R. et al. Sex-dependent differences in inflammatory responses during liver regeneration in a murine model of acute liver injury. Clin Sci (Lond) 2018; 132 (02) 255-272
• 79 Sayaf K, Zanotto I, Gabbia D. et al. Sex drives functional changes in the progression and regression of liver fibrosis. Int J Mol Sci 2023; 24 (22) 24
• 80 Birrer DL, Linecker M, López-López V. et al. Sex disparities in outcomes following major liver surgery: new powers of estrogen?. Ann Surg 2022; 276 (05) 875-881
• 81 Zhu M, Li Y, Shen Q, Gong Z, Liu D. Sex hormone receptors, calcium-binding protein and Yap1 signaling regulate sex-dependent liver cell proliferation following partial hepatectomy. Dis Model Mech 2024; 17 (10) 17
• 82 Guy J, Peters MG. Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes. Gastroenterol Hepatol (N Y) 2013; 9 (10) 633-639
• 83 Pietrangelo A. Genetics, genetic testing, and management of hemochromatosis: 15 years since hepcidin. Gastroenterology 2015; 149 (05) 1240-1251.e4
• 84 Allen KJ, Gurrin LC, Constantine CC. et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008; 358 (03) 221-230
• 85 Cooper KM, Delk M, Devuni D, Sarkar M. Sex differences in chronic liver disease and benign liver lesions. JHEP Rep Innov Hepatol 2023; 5 (11) 100870
• 86 Shin N, Kim YH, Xu H. et al. Redefining Budd-Chiari syndrome: a systematic review. World J Hepatol 2016; 8 (16) 691-702
• 87 Buzzetti E, Parikh PM, Gerussi A, Tsochatzis E. Gender differences in liver disease and the drug-dose gender gap. Pharmacol Res 2017; 120: 97-108
• 88 Sutti S, Tacke F. Liver inflammation and regeneration in drug-induced liver injury: sex matters!. Clin Sci (Lond) 2018; 132 (05) 609-613
• 89 Chen TS, Doong ML, Chang FY, Lee SD, Wang PS. Effects of sex steroid hormones on gastric emptying and gastrointestinal transit in rats. Am J Physiol 1995; 268 (1 Pt 1): G171-G176
• 90 Yang L, Li Y, Hong H. et al. Sex differences in the expression of drug-metabolizing and transporter genes in human liver. J Drug Metab Toxicol 2012; 3 (03) 1000119
• 91 Lamba V, Lamba J, Yasuda K. et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 2003; 307 (03) 906-922
• 92 Mauvais-Jarvis F, Berthold HK, Campesi I. et al. Sex- and gender-based pharmacological response to drugs. Pharmacol Rev 2021; 73 (02) 730-762
• 93 Lai KP, Wong MH, Wong CK. Modulation of AhR-mediated CYP1A1 mRNA and EROD activities by 17beta-estradiol and dexamethasone in TCDD-induced H411E cells. Toxicol Sci 2004; 78 (01) 41-49
• 94 Koyuncuoğlu T, Yıldırım A, Dertsiz EK, Yüksel M, Ercan F, Yeğen BÇ. Estrogen receptor agonists protect against acetaminophen-induced hepatorenal toxicity in rats. Life Sci 2020; 263: 118561
• 95 Win S, Min RW, Chen CQ. et al. Expression of mitochondrial membrane-linked SAB determines severity of sex-dependent acute liver injury. J Clin Invest 2019; 129 (12) 5278-5293
• 96 Frezza M, di Padova C, Pozzato G, Terpin M, Baraona E, Lieber CS. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med 1990; 322 (02) 95-99
• 97 Thurman RG. II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Am J Physiol 1998; 275 (04) G605-G611
• 98 Yin M, Ikejima K, Wheeler MD. et al. Estrogen is involved in early alcohol-induced liver injury in a rat enteral feeding model. Hepatology 2000; 31 (01) 117-123
• 99 Ikejima K, Enomoto N, Iimuro Y. et al. Estrogen increases sensitivity of hepatic Kupffer cells to endotoxin. Am J Physiol 1998; 274 (04) G669-G676
• 100 Mishra P, Davies DA, Albensi BC. The interaction between NF-κB and estrogen in Alzheimer's disease. Mol Neurobiol 2023; 60 (03) 1515-1526
• 101 Purawarga Matada GS, Dhiwar PS, Abbas N. et al. Molecular docking and molecular dynamic studies: screening of phytochemicals against EGFR, HER2, estrogen and NF-KB receptors for their potential use in breast cancer. J Biomol Struct Dyn 2022; 40 (13) 6183-6192
• 102 Mezey E. Influence of sex hormones on alcohol metabolism. Alcohol Clin Exp Res 2000; 24 (04) 421
• 103 Ichiro S, Kamochi M, Yoshikawa H, Nakayama Y. Gender Difference in Alcoholic Liver Disease. IntechOpen; 2012
• 104 Kim DK, Kim YH, Jang HH. et al. Estrogen-related receptor γ controls hepatic CB1 receptor-mediated CYP2E1 expression and oxidative liver injury by alcohol. Gut 2013; 62 (07) 1044-1054
• 105 Järveläinen HA, Lukkari TA, Heinaro S, Sippel H, Lindros KO. The antiestrogen toremifene protects against alcoholic liver injury in female rats. J Hepatol 2001; 35 (01) 46-52
• 106 Fang C, Lindros KO, Badger TM, Ronis MJ, Ingelman-Sundberg M. Zonated expression of cytokines in rat liver: effect of chronic ethanol and the cytochrome P450 2E1 inhibitor, chlormethiazole. Hepatology 1998; 27 (05) 1304-1310
• 107 Gouillon Z, Lucas D, Li J. et al. Inhibition of ethanol-induced liver disease in the intragastric feeding rat model by chlormethiazole. Proc Soc Exp Biol Med 2000; 224 (04) 302-308
• 108 Zhu L, Brown WC, Cai Q. et al. Estrogen treatment after ovariectomy protects against fatty liver and may improve pathway-selective insulin resistance. Diabetes 2013; 62 (02) 424-434
• 109 Skubic C, Drakulić Ž, Rozman D. Personalized therapy when tackling nonalcoholic fatty liver disease: a focus on sex, genes, and drugs. Expert Opin Drug Metab Toxicol 2018; 14 (08) 831-841
• 110 Schiffrin M, Winkler C, Quignodon L. et al. Sex dimorphism of nonalcoholic fatty liver disease (NAFLD) in Pparg-null mice. Int J Mol Sci 2021; 22 (18) 22
• 111 Shu Z, Zhang G, Zhu X, Xiong W. Estrogen receptor α mediated M1/M2 macrophages polarization plays a critical role in NASH of female mice. Biochem Biophys Res Commun 2022; 596: 63-70
• 112 Yang M, Liu Q, Huang T. et al. Dysfunction of estrogen-related receptor alpha-dependent hepatic VLDL secretion contributes to sex disparity in NAFLD/NASH development. Theranostics 2020; 10 (24) 10874-10891
• 113 Della Torre S. Beyond the X factor: relevance of sex hormones in NAFLD pathophysiology. Cells 2021; 10 (09) 10
• 114 Sharma G, Prossnitz ER. G-protein-coupled estrogen receptor (GPER) and sex-specific metabolic homeostasis. Adv Exp Med Biol 2017; 1043: 427-453
• 115 Meoli L, Isensee J, Zazzu V. et al. Sex- and age-dependent effects of Gpr30 genetic deletion on the metabolic and cardiovascular profiles of diet-induced obese mice. Gene 2014; 540 (02) 210-216
• 116 Zhang Y, Wu L, Wang Y. et al. Protective role of estrogen-induced miRNA-29 expression in carbon tetrachloride-induced mouse liver injury. J Biol Chem 2012; 287 (18) 14851-14862
• 117 Zhang ZC, Liu Y, Xiao LL. et al. Upregulation of miR-125b by estrogen protects against non-alcoholic fatty liver in female mice. J Hepatol 2015; 63 (06) 1466-1475
• 118 Lee C, Kim J, Han J. et al. Formyl peptide receptor 2 determines sex-specific differences in the progression of nonalcoholic fatty liver disease and steatohepatitis. Nat Commun 2022; 13 (01) 578
• 119 Wu J, Yao XY, Shi RX, Liu SF, Wang XY. A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis. Reprod Health 2018; 15 (01) 77
• 120 Sarkar M, Yates K, Suzuki A. et al. Low testosterone is associated with nonalcoholic steatohepatitis and fibrosis severity in men. Clin Gastroenterol Hepatol 2021; 19 (02) 400-402.e2
• 121 Jaruvongvanich V, Sanguankeo A, Riangwiwat T, Upala S. Testosterone, sex hormone-binding globulin and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Ann Hepatol 2017; 16 (03) 382-394
• 122 Jia Y, Yee JK, Wang C. et al. Testosterone protects high-fat/low-carbohydrate diet-induced nonalcoholic fatty liver disease in castrated male rats mainly via modulating endoplasmic reticulum stress. Am J Physiol Endocrinol Metab 2018; 314 (04) E366-E376
• 123 Nikolaenko L, Jia Y, Wang C. et al. Testosterone replacement ameliorates nonalcoholic fatty liver disease in castrated male rats. Endocrinology 2014; 155 (02) 417-428
• 124 Schwinge D, Schramm C. Sex-related factors in autoimmune liver diseases. Semin Immunopathol 2019; 41 (02) 165-175
• 125 Smyk DS, Rigopoulou EI, Pares A. et al. Sex differences associated with primary biliary cirrhosis. Clin Dev Immunol 2012; 2012: 610504
• 126 Yasuda M, Shimizu I, Shiba M, Ito S. Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats. Hepatology 1999; 29 (03) 719-727
• 127 Xu J-W, Gong J, Chang X-M. et al. Estrogen reduces CCL4- induced liver fibrosis in rats. World J Gastroenterol 2002; 8 (05) 883-887
• 128 Lu G, Shimizu I, Cui X. et al. Antioxidant and antiapoptotic activities of idoxifene and estradiol in hepatic fibrosis in rats. Life Sci 2004; 74 (07) 897-907
• 129 Zhou YJ, Yin DM, Chen HS, Shi JH, Sha BX, Wang X. Inhibitory effects of idoxifene on hepatic fibrosis in rats. Acta Pharmacol Sin 2005; 26 (05) 581-586
• 130 Shimizu I, Ito S. Protection of estrogens against the progression of chronic liver disease. Hepatol Res 2007; 37 (04) 239-247
• 131 Shimizu I, Kohno N, Tamaki K. et al. Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection. World J Gastroenterol 2007; 13 (32) 4295-4305
• 132 Higashi T, Friedman SL, Hoshida Y. Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliv Rev 2017; 121: 27-42
• 133 Zhou Y, Shimizu I, Lu G. et al. Hepatic stellate cells contain the functional estrogen receptor beta but not the estrogen receptor alpha in male and female rats. Biochem Biophys Res Commun 2001; 286 (05) 1059-1065
• 134 Zhang B, Zhang CG, Ji LH, Zhao G, Wu ZY. Estrogen receptor β selective agonist ameliorates liver cirrhosis in rats by inhibiting the activation and proliferation of hepatic stellate cells. J Gastroenterol Hepatol 2018; 33 (03) 747-755
• 135 Zhang K, Lin L, Zhu Y, Zhang N, Zhou M, Li Y. Saikosaponin d alleviates liver fibrosis by negatively regulating the ROS/NLRP3 inflammasome through activating the ERβ pathway. Front Pharmacol 2022; 13: 894981
• 136 Inagaki Y, Okazaki I. Emerging insights into transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut 2007; 56 (02) 284-292
• 137 McCarty MF, Barroso-Aranda J, Contreras F. Genistein and phycocyanobilin may prevent hepatic fibrosis by suppressing proliferation and activation of hepatic stellate cells. Med Hypotheses 2009; 72 (03) 330-332
• 138 Ganai AA, Husain M. Genistein attenuates D-GalN induced liver fibrosis/chronic liver damage in rats by blocking the TGF-β/Smad signaling pathways. Chem Biol Interact 2017; 261: 80-85
• 139 Evans MJ, Lai K, Shaw LJ, Harnish DC, Chadwick CC. Estrogen receptor alpha inhibits IL-1beta induction of gene expression in the mouse liver. Endocrinology 2002; 143 (07) 2559-2570
• 140 Ma X, Zhou Y, Qiao B. et al. Androgen aggravates liver fibrosis by activation of NLRP3 inflammasome in CCl₄-induced liver injury mouse model. Am J Physiol Endocrinol Metab 2020; 318 (05) E817-E829
• 141 Wang S-H, Yeh S-H, Lin W-H, Wang HY, Chen DS, Chen PJ. Identification of androgen response elements in the enhancer I of hepatitis B virus: a mechanism for sex disparity in chronic hepatitis B. Hepatology 2009; 50 (05) 1392-1402
• 142 Wu M-H, Ma W-L, Hsu C-L. et al. Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Sci Transl Med 2010; 2 (32) 32ra35
• 143 Cha MY, Kim CM, Park YM, Ryu WS. Hepatitis B virus X protein is essential for the activation of Wnt/beta-catenin signaling in hepatoma cells. Hepatology 2004; 39 (06) 1683-1693
• 144 Ding Q, Xia W, Liu J-C. et al. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell 2005; 19 (02) 159-170
• 145 Bouchard MJ, Wang L, Schneider RJ. Activation of focal adhesion kinase by hepatitis B virus HBx protein: multiple functions in viral replication. J Virol 2006; 80 (09) 4406-4414
• 146 Yeh S-H, Chen P-J. Gender disparity of hepatocellular carcinoma: the roles of sex hormones. Oncology 2010; 78 (Suppl. 01) 172-179
• 147 Chen P-J, Yeh S-H, Liu W-H. et al. Androgen pathway stimulates microRNA-216a transcription to suppress the tumor suppressor in lung cancer-1 gene in early hepatocarcinogenesis. Hepatology 2012; 56 (02) 632-643
• 148 Feng H, Cheng ASL, Tsang DP. et al. Cell cycle-related kinase is a direct androgen receptor-regulated gene that drives β-catenin/T cell factor-dependent hepatocarcinogenesis. J Clin Invest 2011; 121 (08) 3159-3175
• 149 Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005; 40 (03) 225-235
• 150 Zhang H, Spencer K, Burley SK, Zheng XFS. Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma. Drug Discov Today 2021; 26 (06) 1539-1546
• 151 Ji F, Zhang J, Liu N. et al. Blocking hepatocarcinogenesis by a cytochrome P450 family member with female-preferential expression. Gut 2022; 71 (11) 2313-2324
• 152 Naugler WE, Sakurai T, Kim S. et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317 (5834): 121-124
• 153 Hou J, Xu J, Jiang R. et al. Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3. Hepatology 2013; 57 (02) 678-688
• 154 Huang F-Y, Wong DK-H, Seto W-K, Lai C-L, Yuen M-F. Estradiol induces apoptosis via activation of miRNA-23a and p53: implication for gender difference in liver cancer development. Oncotarget 2015; 6 (33) 34941-34952
• 155 Li C-L, Yeh K-H, Liu W-H. et al. Elevated p53 promotes the processing of miR-18a to decrease estrogen receptor-α in female hepatocellular carcinoma. Int J Cancer 2015; 136 (04) 761-770
• 156 Wei Q, Guo P, Mu K. et al. Estrogen suppresses hepatocellular carcinoma cells through ERβ-mediated upregulation of the NLRP3 inflammasome. Lab Invest 2015; 95 (07) 804-816
• 157 Chow PK, Tai BC, Tan CK. et al; Asian-Pacific Hepatocellular Carcinoma Trials Group. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology 2002; 36 (05) 1221-1226
• 158 Riestra S, Rodriguez M, Delgado M. et al. Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma. J Clin Gastroenterol 1998; 26 (03) 200-203
• 159 Shimizu I. CLIP Group (Cancer of the Liver Italian Programme). Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. Lancet 1998; 352 (9121): 17-20
• 160 Barbare JC, Bouché O, Bonnetain F. et al. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol 2005; 23 (19) 4338-4346
• 161 Harada H, Pavlick KP, Hines IN. et al. Selected contribution: effects of gender on reduced-size liver ischemia and reperfusion injury. J Appl Physiol 2001; 91 (06) 2816-2822
• 162 Harada H, Pavlick KP, Hines IN. et al. Sexual dimorphism in reduced-size liver ischemia and reperfusion injury in mice: role of endothelial cell nitric oxide synthase. Proc Natl Acad Sci U S A 2003; 100 (02) 739-744
• 163 Harada H, Bharwani S, Pavlick KP, Korach KS, Grisham MB. Estrogen receptor-alpha, sexual dimorphism and reduced-size liver ischemia and reperfusion injury in mice. Pediatr Res 2004; 55 (03) 450-456
• 164 Fels JA, Manfredi G. Sex differences in ischemia/reperfusion injury: the role of mitochondrial permeability transition. Neurochem Res 2019; 44 (10) 2336-2345
• 165 Huang C, Gu H, Zhang W, Herrmann JL, Wang M. Testosterone-down-regulated Akt pathway during cardiac ischemia/reperfusion: a mechanism involving BAD, Bcl-2 and FOXO3a. J Surg Res 2010; 164 (01) e1-e11
• 166 Wang M, Tsai BM, Kher A, Baker LB, Wairiuko GM, Meldrum DR. Role of endogenous testosterone in myocardial proinflammatory and proapoptotic signaling after acute ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2005; 288 (01) H221-H226
• 167 Liddle C, Farrell GC. Role of the oestrogen receptor in liver regeneration in the male rat. J Gastroenterol Hepatol 1993; 8 (06) 524-529
• 168 Francavilla A, di Leo A, Eagon PK. et al. Regenerating rat liver: correlations between estrogen receptor localization and deoxyribonucleic acid synthesis. Gastroenterology 1984; 86 (03) 552-557
• 169 Fisher B, Gunduz N, Saffer EA, Zheng S. Relation of estrogen and its receptor to rat liver growth and regeneration. Cancer Res 1984; 44 (06) 2410-2415
• 170 Francavilla A, Eagon PK, DiLeo A. et al. Sex hormone-related functions in regenerating male rat liver. Gastroenterology 1986; 91 (05) 1263-1270
• 171 Kao TL, Kuan YP, Cheng WC. et al. Estrogen receptors orchestrate cell growth and differentiation to facilitate liver regeneration. Theranostics 2018; 8 (10) 2672-2682
• 172 Chaturantabut S, Shwartz A, Evason KJ. et al. Estrogen activation of G-Protein-coupled estrogen receptor 1 regulates phosphoinositide 3-kinase and mTOR signaling to promote liver growth in zebrafish and proliferation of human hepatocytes. Gastroenterology 2019; 156 (06) 1788-1804.e13
• 173 Yamaguchi M, Yu L, Nazmy El-Assal O. et al. Androgen metabolism in regenerating liver of male rats: evidence for active uptake and utilization of testosterone. Hepatol Res 2001; 20 (01) 114-127
• 174 Du L, Bayir H, Lai Y. et al. Innate gender-based proclivity in response to cytotoxicity and programmed cell death pathway. J Biol Chem 2004; 279 (37) 38563-38570
• 175 Barker JM, Torregrossa MM, Arnold AP, Taylor JR. Dissociation of genetic and hormonal influences on sex differences in alcoholism-related behaviors. J Neurosci 2010; 30 (27) 9140-9144
• 176 Chen X, McClusky R, Chen J. et al. The number of x chromosomes causes sex differences in adiposity in mice. PLoS Genet 2012; 8 (05) e1002709
• 177 Romeo S. Notch and nonalcoholic fatty liver and fibrosis. N Engl J Med 2019; 380 (07) 681-683
• 178 Zhu C, Kim K, Wang X. et al. Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. Sci Transl Med 2018; 10 (468) 10
• 179 Hanley KP, Oakley F, Sugden S, Wilson DI, Mann DA, Hanley NA. Ectopic SOX9 mediates extracellular matrix deposition characteristic of organ fibrosis. J Biol Chem 2008; 283 (20) 14063-14071
• 180 Pritchett J, Harvey E, Athwal V. et al. Osteopontin is a novel downstream target of SOX9 with diagnostic implications for progression of liver fibrosis in humans. Hepatology 2012; 56 (03) 1108-1116
• 181 Athwal VS, Pritchett J, Llewellyn J. et al. SOX9 predicts progression toward cirrhosis in patients while its loss protects against liver fibrosis. EMBO Mol Med 2017; 9 (12) 1696-1710
• 182 Fu M, Yin W, Zhang W, Zhu Y, Ni H, Gong L. MicroRNA-15a inhibits hepatic stellate cell activation and proliferation via targeting SRY-box transcription factor 9. Bioengineered 2022; 13 (05) 13011-13020
• 183 Wang C, Deng J, Deng H. et al. A novel Sox9/lncRNA H19 axis contributes to hepatocyte death and liver fibrosis. Toxicol Sci 2020; 177 (01) 214-225
• 184 Jiang H-L, Xu D, Yu H. et al. DAX-1 inhibits hepatocellular carcinoma proliferation by inhibiting β-catenin transcriptional activity. Cell Physiol Biochem 2014; 34: 734-742
• 185 Motawi TMK, Sadik NAH, Sabry D, Shahin NN, Fahim SA. rs2267531, a promoter SNP within glypican-3 gene in the X chromosome, is associated with hepatocellular carcinoma in Egyptians. Sci Rep 2019; 9 (01) 6868
• 186 Liao YL, Sun YM, Chau GY. et al. Identification of SOX4 target genes using phylogenetic footprinting-based prediction from expression microarrays suggests that overexpression of SOX4 potentiates metastasis in hepatocellular carcinoma. Oncogene 2008; 27 (42) 5578-5589
• 187 Wang W, Zhang J, Zhan X. et al. SOX4 is associated with poor prognosis in cholangiocarcinoma. Biochem Biophys Res Commun 2014; 452 (03) 614-621
• 188 Kawaguchi Y. Sox9 and programming of liver and pancreatic progenitors. J Clin Invest 2013; 123 (05) 1881-1886
• 189 Tsai C-N, Yu S-C, Lee C-W. et al. SOX4 activates CXCL12 in hepatocellular carcinoma cells to modulate endothelial cell migration and angiogenesis in vivo. Oncogene 2020; 39 (24) 4695-4710
• 190 Tsuei D-J, Hsu H-C, Lee P-H. et al. RBMY, a male germ cell-specific RNA-binding protein, activated in human liver cancers and transforms rodent fibroblasts. Oncogene 2004; 23 (34) 5815-5822
• 191 Chua H-H, Tsuei D-J, Lee P-H. et al. RBMY, a novel inhibitor of glycogen synthase kinase 3β, increases tumor stemness and predicts poor prognosis of hepatocellular carcinoma. Hepatology 2015; 62 (05) 1480-1496
• 192 Li S, Mo C, Huang S. et al. Over-expressed Testis-specific Protein Y-encoded 1 as a novel biomarker for male hepatocellular carcinoma. PLoS One 2014; 9 (02) e89219
• 193 Fan XD, Zheng HB, Fan XS, Lu S. Increase of SOX9 promotes hepatic ischemia/reperfusion (IR) injury by activating TGF-β1. Biochem Biophys Res Commun 2018; 503 (01) 215-221
• 194 Han X, Wang Y, Pu W. et al. Lineage tracing reveals the bipotency of SOX9⁺ hepatocytes during liver regeneration. Stem Cell Reports 2019; 12 (03) 624-638
• 195 Yovchev MI, Locker J, Oertel M. Biliary fibrosis drives liver repopulation and phenotype transition of transplanted hepatocytes. J Hepatol 2016; 64 (06) 1348-1357
• 196 Shao C, Jing Y, Zhao S. et al. LPS/Bcl3/YAP1 signaling promotes Sox9⁺HNF4α⁺ hepatocyte-mediated liver regeneration after hepatectomy. Cell Death Dis 2022; 13 (03) 277
• 197 Gong S, Zeng Y, Wang Z. et al. Intestinal deguelin drives resistance to acetaminophen-induced hepatotoxicity in female mice. Gut Microbes 2024; 16 (01) 2404138
• 198 Corpechot C, Chrétien Y, Chazouillères O, Poupon R. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol 2010; 53 (01) 162-169
• 199 Gershwin ME, Selmi C, Worman HJ. et al; USA PBC Epidemiology Group. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005; 42 (05) 1194-1202
• 200 Prince MI, Ducker SJ, James OF. Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations. Gut 2010; 59 (04) 508-512
• 201 Karlsen TH, Lammert F, Thompson RJ. Genetics of liver disease: from pathophysiology to clinical practice. J Hepatol 2015; 62 (1, Suppl): S6-S14
• 202 Greten TF. Gender disparity in HCC: is it the fat and not the sex?. J Exp Med 2019; 216 (05) 1014-1015
• 203 Manieri E, Herrera-Melle L, Mora A. et al. Adiponectin accounts for gender differences in hepatocellular carcinoma incidence. J Exp Med 2019; 216 (05) 1108-1119
• 204 Yang Q, Yan C, Yin C, Gong Z. Serotonin activated hepatic stellate cells contribute to sex disparity in hepatocellular carcinoma. Cell Mol Gastroenterol Hepatol 2017; 3 (03) 484-499
• 205 Hu Z, Jepps TA, Zhou L, Liu J, Li M, Abbott GW. Kcne4 deletion sex dependently inhibits the RISK pathway response and exacerbates hepatic ischemia-reperfusion injury in mice. Am J Physiol Regul Integr Comp Physiol 2019; 316 (05) R552-R562
• 206 Shang D, Wang L, Klionsky DJ, Cheng H, Zhou R. Sex differences in autophagy-mediated diseases: toward precision medicine. Autophagy 2021; 17 (05) 1065-1076
• 207 Campana L, Esser H, Huch M, Forbes S. Liver regeneration and inflammation: from fundamental science to clinical applications. Nat Rev Mol Cell Biol 2021; 22 (09) 608-624
• 208 Shimizu I. Accounting for sex and gender makes for better science. Nature 2020; 588 (7837): 196
• 209 Hunt L, Nielsen MW, Schiebinger L. A framework for sex, gender, and diversity analysis in research. Science 2022; 377 (6614): 1492-1495
• 210 Peters SAE, Woodward M. A roadmap for sex- and gender-disaggregated health research. BMC Med 2023; 21 (01) 354
• 211 de Beaurepaire R. Suppression of alcohol dependence using baclofen: a 2-year observational study of 100 patients. Front Psychiatry 2012; 3: 103
• 212 Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and treatment of alcohol-associated liver diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology 2020; 71 (01) 306-333
• 213 Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology 2020; 158 (07) 1851-1864
• 214 Li N, Cui C, Xu J, Mi M, Wang J, Qin Y. Quercetin intervention reduced hepatic fat deposition in patients with nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled crossover clinical trial. Am J Clin Nutr 2024; 120 (03) 507-517
• 215 Yan H, Wu W, Chang X. et al. Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism. Biol Sex Differ 2021; 12 (01) 1
• 216 Carbone M, Mells GF, Pells G. et al; UK PBC Consortium. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology 2013; 144 (03) 560-569.e7 , quiz e13–e14
• 217 Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet 2015; 386 (10003): 1565-1575
• 218 Hirschfield GM, Dyson JK, Alexander GJM. et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut 2018; 67 (09) 1568-1594
• 219 Muratori L, Lohse AW, Lenzi M. Diagnosis and management of autoimmune hepatitis. BMJ 2023; 380: e070201
• 220 Czaja AJ, Donaldson PT. Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. Am J Gastroenterol 2002; 97 (08) 2051-2057
• 221 Al-Chalabi T, Underhill JA, Portmann BC, McFarlane IG, Heneghan MA. Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. J Hepatol 2008; 48 (01) 140-147
• 222 Kim MN, Han JW, An J. et al; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease. Clin Mol Hepatol 2024; 30 (Suppl): S5-S105
• 223 Shimizu I. Chinese Society of Hepatology Chinese Medical Association, Chinese Society of Gastroenterology Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. [Consensus on the diagnosis and therapy of hepatic fibrosis in]. Zhonghua Gan Zang Bing Za Zhi 2019; 27 (09) 657-667
• 224 Kammula AV, Schäffer AA, Rajagopal PS, Kurzrock R, Ruppin E. Outcome differences by sex in oncology clinical trials. Nat Commun 2024; 15 (01) 2608
• 225 D'Abbondanza M, Ministrini S, Pucci G. et al. Very Low-Carbohydrate Ketogenic Diet for the Treatment of Severe Obesity and Associated Non-Alcoholic Fatty Liver Disease: The Role of Sex Differences. Nutrients 2020;12